Navigation Links
IU Confidential Publishes Biotech Investment Report

NEW YORK, July 28, 2011 /PRNewswire/ -- Investor Uprising Confidential, the premium investment research service of Investor Uprising, has published its "Best of Biotech: Innovation in Life Sciences" report today. The 16-page report covers the hottest trends in biotech investing, tells investors how to get involved, and gives an overview of more than 16 companies including a model portfolio of 10 top stock picks.


Biotech stocks have been among the best performers of the last five years, according to Investor Uprising Confidential's research, and many of these gains are driven by scientific innovation in the biopharmaceuticals and diagnostics markets. This innovation cycle is likely to continue for some time, making biotech an attractive place to invest.

"Many investors remain unaware of the strength in biotech and are mystified about how to invest in the market," says Investor Uprising Confidential's Editor and Publisher, R. Scott Raynovich. "Consequently, they have missed out. We put together a report that covers all the trends and explains many different ways to get involved, including ETFs, mutual funds, and individual stocks."

The report includes summaries of 17 leading biotechnology companies, three mutual funds, and the leading biotech Exchange Traded Funds (ETFs). Among the companies included in the report are Amgen Inc. (Nasdaq: AMGN), Biogen Idec  (Nasdaq: BIIB), Celgene Inc. (Nasdaq: CELG), Gilead Sciences Inc. (Nasdaq: GILD), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX), BioMarin Pharmaceutical Inc. (Nasdaq: BMRN), Cubist Pharmaceuticals Inc. (Nasdaq: CBST), Dendreon Corp. (Nasdaq: DNDN), Illumina Inc. (Nasdaq: ILMN), and Seattle Genetics Inc. (Nasdaq: SGEN).

Investor Uprising Confidential produces premium in-depth reports aimed at informing the sophisticated investor about long-term trends in important growth markets. The Best of Biotech report is available as a single copy at $500, or as part of an Investor Uprising Confidential annual subscription. To look at the executive summary of the Biotech and the research service, go to

Sponsored by PR Newswire, Investor Uprising, as well as the recent launch of the "My News" feature on and monthly virtual Retail Investor Conferences (, represents PR Newswire's strategy to facilitate engagement between the individual investor community and public companies.

About Investor Uprising

Investor Uprising is the individual investor's no-nonsense community for accessing business trends and investment strategies. Combining expert market commentary, fundamental analysis and on-the-ground reporting, Investor Uprising helps the reader find the best investment opportunities in global markets. Sponsored by PR Newswire and operated by UBM plc, Investor Uprising's community of contributors will reach millions of potential business readers around the world.

Media Contacts:
R. Scott Raynovich
Editor in Chief, Investor Uprising Confidential
(406) 582-5886 direct
(406) 599-7873 mobile

Noreen Seebacher
Community Editor, Investor Uprising
(201) 360-6773

SOURCE Investor Uprising
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cellceutix Reports Confidential Disclosure Agreement Signed With Major Pharmaceutical Company
2. New Medical Supply Website Provides Confidentiality, Discounts for Consumers
3. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
4. GSK Publishes Payments for Research, Consulting and Advising by U.S. Healthcare Professionals
5. The Journal of Clinical Oncology Publishes Phase 3 XGEVA™ (Denosumab) Results in Advanced Cancer Patients With Solid Tumors or Multiple Myeloma
6. Extreme Makeover for Healthcare Next Year? PwC Publishes its Top Health Industry Issues for 2011
7. Radiology Journal Publishes Data That PEM Scanners May Reduce Unnecessary Breast Biopsies and Offer an Alternative for Women Who Cannot Tolerate MRI
8. Cellectis Publishes Its Financial Statement for the First Half of 2010
9. Obstetrics and Gynecology Publishes Data From Pivotal Phase 3 LYSTEDA Study
10. Siemens Healthcare Diagnostics Publishes Global Trade Item Numbers (GTINs) for its Entire U.S. Product Line to the GHX Health ConneXion(SM) Data Pool
11. The ASCO Post Publishes Multiple Perspectives on Outcome of ODAC Meeting Regarding Bevacizumab in Advanced Breast Cancer
Post Your Comments:
(Date:11/26/2015)... 2015 Research and Markets ( ) has ... Market Outlook to 2019 - Rise in Cardiac Disorders and ... report to their offering. Boston ... scientific and others. --> The ... Boston scientific and others. ...
(Date:11/26/2015)... -- Research and Markets ( ) has ... Horizons and Growth Strategies in the Japanese Therapeutic ... Forecasts, Competitive Intelligence, Emerging Opportunities" report to ... --> This new 247-page report provides ... monitoring market, including emerging tests, technologies, instrumentation, sales ...
(Date:11/26/2015)... DUBLIN , November 26, 2015 ... has announced the addition of the  ... in the Global Cell Surface Testing ... Opportunities" report to their offering.  ... the addition of the  "2016 Future ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... convenient way to dispense prescription medications at home, so he invented the patent-pending ... monitor and dispense prescription medications. In doing so, it could help to prevent ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... online platform for mental health and wellness consultation, has collaborated with a leading ... bridge the knowledge gap experienced by parents and bring advice from parenting experts ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft ... announces the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite ... LTS brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive ...
(Date:11/26/2015)... ... 2015 , ... The Catalent Applied Drug Delivery Institute today ... dose form selection in early phase drug development. The first of these is ... together the UK’s emerging life sciences companies, corporate partners, and investors, at Milton ...
Breaking Medicine News(10 mins):